Alpine Immune Sciences (ALPN) is scheduled to resume trading at 4:30 pm ET, with quotation set to resume at 4:25 pm ET, according to Nasdaq. Shares were halted, pending news, ahead of Alpine and Vertex Pharmaceuticals (VRTX) announcing that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9B in cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN:
- Alpine Immune Sciences initiated with a Buy at Guggenheim
- Alpine Immune Sciences Announces New Chief Accounting Officer
- Biotech Alert: Searches spiking for these stocks today
- Vera Therapeutics price target raised to $34 from $21 at Wedbush
- Alpine Immune Sciences’ Growth at Risk: Navigating FDA and SEC Disruptions Amidst Political and Health Uncertainties
